89bio, Inc. (ETNB)
Largest Insider Buys in Sector
ETNB Stock Price History Chart
ETNB Stock Performance
About 89bio, Inc.
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Insider Activity of 89bio, Inc.
Over the last 12 months, insiders at 89bio, Inc. have bought $20.72M and sold $1.41M worth of 89bio, Inc. stock.
On average, over the past 5 years, insiders at 89bio, Inc. have bought $37.95M and sold $4.53M worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $518.06M.
The last purchase of 1,350,000 shares for transaction amount of $20.72M was made by RA CAPITAL MANAGEMENT, L.P. () on 2024‑03‑04.
List of Insider Buy and Sell Transactions, 89bio, Inc.
| 2024-10-30 | Sale | See Remarks | 27,955 0.0268% | $8.12 | $226,995 | +13.83% | ||
| 2024-04-01 | Sale | Chief Executive Officer | 52,718 0.0573% | $10.91 | $575,153 | -20.50% | ||
| 2024-03-04 | 1.35M 1.6718% | $15.35 | $20.72M | -36.61% | ||||
| 2024-02-26 | Sale | Chief Executive Officer | 4,477 0.0047% | $10.76 | $48,173 | -20.40% | ||
| 2023-12-29 | Sale | Chief Executive Officer | 50,000 0.0549% | $11.20 | $560,000 | -19.79% | ||
| 2023-07-17 | Sale | director | 12,500 0.024% | $18.80 | $235,000 | -43.21% | ||
| 2023-06-05 | Sale | Chief Executive Officer | 15,000 0.0282% | $20.00 | $300,000 | -44.75% | ||
| 2023-06-01 | Sale | director | 6,250 0.0112% | $17.91 | $111,938 | -41.25% | ||
| 2023-05-09 | Sale | See Remarks | 13,683 0.0258% | $18.11 | $247,799 | -36.64% | ||
| 2023-04-04 | Sale | Chief Financial Officer | 8,721 0.0165% | $14.95 | $130,379 | -2.87% | ||
| 2023-03-28 | director | 61,538 0.112% | $16.15 | $993,839 | -11.14% | |||
| 2023-03-24 | 2.46M 4.6238% | $16.25 | $40M | -7.38% | ||||
| 2023-03-23 | Sale | Chief Executive Officer | 15,000 0.0266% | $16.00 | $240,000 | -10.98% | ||
| 2023-03-23 | Sale | Chief Financial Officer | 5,000 0.0089% | $16.11 | $80,550 | -10.98% | ||
| 2023-03-01 | Sale | director | 10,000 0.0184% | $13.60 | $136,000 | +8.33% | ||
| 2023-02-21 | Sale | Chief Financial Officer | 2,540 0.0048% | $13.89 | $35,281 | +8.71% | ||
| 2023-02-08 | Sale | Chief Financial Officer | 1,480 0.0027% | $14.41 | $21,327 | +3.28% | ||
| 2023-02-03 | Sale | Chief Financial Officer | 3,592 0.0067% | $13.04 | $46,848 | +14.12% | ||
| 2023-01-03 | Sale | Chief Financial Officer | 5,947 0.0117% | $12.51 | $74,397 | +26.15% | ||
| 2022-10-18 | director | 1.17M 2.9627% | $7.65 | $8.97M | +74.54% |
Insider Historical Profitability
| RA CAPITAL MANAGEMENT, L.P. | 12431584 10.5727% | $8.77 | 10 | 0 | <0.0001% | |
| PALEKAR ROHAN | Chief Executive Officer | 459171 0.3905% | $8.77 | 4 | 5 | <0.0001% |
| Shah Rajeev M. | 7782669 6.6189% | $8.77 | 1 | 0 | +239.97% | |
| Longitude Capital Partners III, LLC | 10 percent owner | 2600877 2.212% | $8.77 | 2 | 0 | +2.62% |
| Naschitz Anat | 1864721 1.5859% | $8.77 | 1 | 1 | +28.8% |
Institutional Investor Ownership
| RA Capital Management, L.P. | $148.61M | 12.98 | 12.77M | +11.82% | +$15.71M | 0.15 | |
| Janus Henderson | $146.65M | 12.81 | 12.6M | +41.37% | +$42.91M | 0.07 | |
| RTW Investments, LP | $85.89M | 7.5 | 7.38M | +32.26% | +$20.95M | 1.29 | |
| BlackRock | $77.27M | 6.75 | 6.64M | +21.7% | +$13.78M | <0.01 | |
| Suvretta Capital Management, LLC | $73.31M | 6.4 | 6.3M | +28.84% | +$16.41M | 3.1 |